Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease that is common in adults. 1 Most patients obtain disease control with trigger avoidance, and frequent use of emollients and anti-inflammatory topical treatments. However, some patients need systemic therapy to reduce AD activity and severity. A few systemic immunomodulating drugs have traditionally been used for the treatment of AD including methotrexate and azathioprine, although only cyclosporine is approved in Europe.Dupilumab, a monoclonal antibody targeting the IL-4Rα-subunit of the IL4 and IL13-receptor, reduces type 2 inflammation. In January 2018, dupilumab was approved in Denmark for treatment of adults with moderate-tosevere AD. Real-world evidence studies have confirmed the